The second intracellular loop of the yeast Trk1 potassium transporter is involved in regulation of activity, and interaction with 14-3-3 proteins.

Potassium is an essential intracellular ion, and a sufficient intracellular concentration of it is crucial for many processes; therefore it is fundamental for cells to precisely regulate K uptake and efflux through the plasma membrane. The uniporter Trk1 is a key player in K acquisition in yeasts. The gene is expressed at a low and stable level; thus the activity of the transporter needs to be regulated at a posttranslational level.

Comparison of Intravenous and Topical Tranexamic Acid in Total Joint Arthroplasty.

PURPOSE OF THE STUDY To compare topical and intravenous (IV) administration of tranexamic acid (TXA) 2 g in patients undergoing total hip arthroplasty (THA), or total knee arthroplasty (TKA). MATERIAL AND METHODS In total, 452 patients undergoing THA or TKA were randomised to 3 groups: 1) the IV TXA group received 2 doses of TXA 1 g intravenously 3 hours apart; 2) the topical TXA group received TXA 2 g topically, and 3) the NO TXA - control group. Furthermore, each group was divided in two subgroups by performed surgery (THA versus TKA).

Yeast Trk1 Potassium Transporter Gradually Changes Its Affinity in Response to Both External and Internal Signals.

Yeasts need a high intracellular concentration of potassium to grow. The main K uptake system in is the Trk1 transporter, a complex protein with four MPM helical membrane motifs. Trk1 has been shown to exist in low- or high-affinity modes, which reflect the availability of potassium in the environment.

Minority potassium-uptake system Trk2 has a crucial role in yeast survival of glucose-induced cell death.

The existence of programmed cell death in has been reported for many years. Glucose induces the death of in the absence of additional nutrients within a few hours, and the absence of active potassium uptake makes cells highly sensitive to this process. cells possess two transporters, Trk1 and Trk2, which ensure a high intracellular concentration of potassium, necessary for many physiological processes.

[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?].

Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events. We present a case of acute limb ischaemia due to thrombotic occlusion of the superficial femoral artery on the non-operated limb following a total hip arthroplasty in a 64-year-old male patient. Untreated peripheral artery disease, intravenous TXA administration, surgery, obesity and hypertension were identified as predisposing factors of the occlusion.